NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

TA616 Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis

**Matrix of consultees and commentators**

|  |  |
| --- | --- |
| **Consultees** | **Commentators (no right to submit or appeal)** |
| Company   * Merck (cladribine)   Patient/carer groups   * Brain and Spine Foundation * Brain Charity * Disability Rights UK * Leonard Cheshire Disability * MS-UK * Multiple Sclerosis National Therapy Centres * Multiple Sclerosis Society * Multiple Sclerosis Trust * Neurological Alliance * Shift.ms * South Asian Health Foundation * Specialised Healthcare Alliance * Sue Ryder   Healthcare professional groups   * Association of British Neurologists * Association of Neuroscience Nurses * British Geriatrics Society * British Neuropathological Society * British Society of Blood and Marrow Transplantation * British Society of Rehabilitation Medicine * Chartered Society of Physiotherapy * Institute of Neurology * National Neurosciences Advisory Group * Primary Care and Community Neurology Society * Royal College of General Practitioners * Royal College of Nursing * Royal College of Occupational Therapists * Royal College of Pathologists * Royal College of Physicians * Royal Pharmaceutical Society * Royal Society of Medicine * Therapists in MS (TIMS) * UK Clinical Pharmacy Association * UK Multiple Sclerosis Specialist Nurse Association   Others   * Department of Health and Social Care * NHS England * Welsh Government | General commentators   * All Wales Therapeutics and Toxicology Centre * Allied Health Professionals Federation * Board of Community Health Councils in Wales * British National Formulary * Care Quality Commission * Department of Health Northern Ireland * Healthcare Improvement Scotland * Medicines and Healthcare Products Regulatory Agency * Multiple Sclerosis Society * National Association of Primary Care * National Pharmacy Association * Neurological Alliance of Scotland * NHS Alliance * NHS Confederation * Scottish Medicines Consortium * Wales Neurological Alliance * Welsh Health Specialised Services Committee   Comparators   * Biogen (dimethyl fumarate, interferon beta 1a, natalizumab) * Sanofi Genzyme (alemtuzumab, teriflunomide)   Relevant research groups   * Brain Research UK * Cochrane Multiple Sclerosis Group * Genomics England * MRC Clinical Trials Unit * National Hospital for Neurology and Neurosurgery * National Institute for Health Research   Associated Public Health Groups   * Public Health Wales * UK Health Security Agency |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, and the British National Formulary.

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.